AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.05M | 8.32M | 44.85M | 8.96M | 17.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.05M | 8.32M | 44.85M | 8.96M | 17.08M |
| Cost of Revenue | 45.99M | 46.66M | 50.09M | 55.03M | 39.21M |
| Gross Profit | -41.94M | -38.35M | -5.24M | -46.07M | -22.13M |
| SG&A Expenses | 13.85M | 12.33M | 17.22M | 24.96M | 21.99M |
| Depreciation & Amortization | 6.99M | 6.84M | 6.12M | 5.25M | 5.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.83M | 65.83M | 73.44M | 85.23M | 66.67M |
| Operating Income | -62.78M | -57.52M | -28.58M | -76.28M | -49.59M |
| Income Before Tax | -58.97M | -49.54M | -19.50M | -68.77M | -36.34M |
| Income Tax Expenses | -3.54M | -6.37M | -10.55M | -11.65M | -1.62M |
| Earnings from Continuing Operations | -55.43M | -43.17M | -8.95M | -57.12M | -34.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.43M | -43.17M | -8.95M | -57.12M | -34.73M |
| EBIT | -62.78M | -57.52M | -28.58M | -76.28M | -49.59M |
| EBITDA | -55.79M | -50.68M | -22.46M | -71.03M | -44.11M |
| EPS Basic | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 |
| Normalized Basic EPS | -0.12 | -0.10 | -0.04 | -0.14 | -0.08 |
| EPS Diluted | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 |
| Normalized Diluted EPS | -0.12 | -0.10 | -0.04 | -0.14 | -0.08 |
| Average Basic Shares Outstanding | 305.56M | 303.07M | 299.73M | 298.88M | 298.51M |
| Average Diluted Shares Outstanding | 305.56M | 303.07M | 299.73M | 298.88M | 298.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |